• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Thursday

    7/27/23 12:17:02 PM ET
    $ABVC
    $ACXP
    $ADTX
    $AREB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

     

    During Thursday, 56 stocks hit new 52-week lows.

    52-Week Low Highlights:

    • Bristol-Myers Squibb (NYSE:BMY) was the biggest company in terms of market cap to set a new 52-week low.
    • American Rebel Holdings (NASDAQ:AREB) was the smallest company in terms of market cap to set a new 52-week low.
    • View (NASDAQ:VIEW)'s stock moved significantly downwards, trading down 5230.71% to reach a new 52-week low.
    • CBL International (NASDAQ:BANL) saw the sharpest rebound, as shares ascended 0.09%, reversing after hiting a new 52-week low.

    Stocks dropping to new 52-week lows on Thursday:

    • Bristol-Myers Squibb (NYSE:BMY) stock broke to a new 52-week low of $60.38 on Thursday. Shares of the company traded down 2.93%.
    • TC Energy (NYSE:TRP) stock hit a new 52-week low of $36.41. The stock was down 1.73% on the session.
    • NovoCure (NASDAQ:NVCR) shares moved down 12.74% on Thursday to hit a new 52-week low of $34.66, drifting down 12.74%.
    • TELUS Intl (NYSE:TIXT) shares hit a yearly low of $9.58. The stock was down 1.34% on the session.
    • MaxLinear (NASDAQ:MXL) stock hit $22.55 on Thursday morning, setting a new 52-week low for a change of down 22.53%.
    • Nexa Res (NYSE:NEXA) shares set a new 52-week low of $4.13. The stock traded down 1.17%.
    • Shyft Group (NASDAQ:SHYF) stock broke to a new 52-week low of $14.14 on Thursday. Shares of the company traded down 29.01%.
    • uniQure (NASDAQ:QURE) shares set a new 52-week low of $9.37. The stock traded up 0.63%.
    • Sharecare (NASDAQ:SHCR) shares fell to $1.15 on Thursday, setting a new 52-week low with a shift of down 9.33%.
    • Luxfer Holdings (NYSE:LXFR) stock hit a yearly low of $12.53. The stock was down 6.72% for the day.
    • Stoke Therapeutics (NASDAQ:STOK) shares were up 0.17% for the day, having made a 52-week low of $5.88.
    • Prelude Therapeutics (NASDAQ:PRLD) shares set a new 52-week low of $4.06. The stock traded down 0.73%.
    • XOMA (NASDAQ:XOMA) stock achieved a new 52-week low on Thursday morning, hitting $15.22 and moving up 1.1%.
    • FibroGen (NASDAQ:FGEN) stock hit a yearly low of $1.82. The stock was down 2.14% for the day.
    • Kezar Life Sciences (NASDAQ:KZR) stock hit $2.19 on Thursday morning, setting a new 52-week low for a change of down 2.88%.
    • Complete Solaria (NASDAQ:CSLR) stock drifted down 7.25% on Thursday morning to hit a new 52-week low of $4.15.
    • NioCorp Developments (NASDAQ:NB) shares set a new 52-week low of $4.52. The stock traded down 0.22%.
    • Beyond Air (NASDAQ:XAIR) stock dropped to a yearly low on Thursday of $3.31. Shares traded down 2.9%.
    • Mersana Therapeutics (NASDAQ:MRSN) stock drifted down 76.38% on Thursday morning to hit a new 52-week low of $0.80.
    • Intensity Therapeutics (NASDAQ:INTS) shares reached a new 52-week low of $5.40 on Thursday morning, moving down 3.89%.
    • MSP Recovery (NASDAQ:LIFW) shares set a new yearly low of $0.20 this morning. The stock was down 7.16% on the session.
    • Celularity (NASDAQ:CELU) shares were up 3.03% for the day, having made a 52-week low of $0.34.
    • Integra Resources (AMEX:ITRG) shares moved down 1.45% on Thursday to hit a new 52-week low of $0.88, drifting down 1.45%.
    • CBL International (NASDAQ:BANL) shares were down 0.09% for the day, having made a 52-week low of $1.59.
    • Nautilus (NYSE:NLS) stock achieved a new 52-week low on Thursday morning, hitting $1.03 and moving down 2.8%.
    • Yellow (NASDAQ:YELL) stock set a new 52-week low of $0.43 on Thursday, moving down 43.14%.
    • Leap Therapeutics (NASDAQ:LPTX) shares moved down 6.2% on Thursday to hit a new 52-week low of $2.38, drifting down 6.2%.
    • View (NASDAQ:VIEW) shares set a new yearly low of $6.08 this morning. The stock was up 5230.71% on the session.
    • ATI Physical Therapy (NYSE:ATIP) stock hit a yearly low of $6.12. The stock was down 7.8% for the day.
    • Purple Biotech (NASDAQ:PPBT) stock hit a yearly low of $1.14. The stock was down 1.69% for the day.
    • Acurx Pharmaceuticals (NASDAQ:ACXP) shares fell to $1.80 on Thursday, setting a new 52-week low with a shift of down 4.71%.
    • Yunji (NASDAQ:YJ) stock hit $1.05 on Thursday morning, setting a new 52-week low for a change of down 1.87%.
    • Better Therapeutics (NASDAQ:BTTX) stock dropped to a yearly low on Thursday of $0.57. Shares traded down 4.29%.
    • BioCardia (NASDAQ:BCDA) shares hit a yearly low of $0.88. The stock was down 6.61% on the session.
    • Capstone Green Energy (NASDAQ:CGRN) stock hit a yearly low of $0.97. The stock was down 11.31% for the day.
    • Addentax Group (NASDAQ:ATXG) stock drifted down 2.12% on Thursday morning to hit a new 52-week low of $3.65.
    • Lytus Technologies Hldgs (NASDAQ:LYT) shares moved down 12.74% on Thursday to hit a new 52-week low of $0.31, drifting down 12.74%.
    • Greenbrook TMS (NASDAQ:GBNH) shares set a new 52-week low of $0.23. The stock traded up 2.74%.
    • ABVC BioPharma (NASDAQ:ABVC) stock set a new 52-week low of $3.26 on Thursday, moving down 37.59%.
    • Golden Minerals (AMEX:AUMN) stock drifted down 1.55% on Thursday morning to hit a new 52-week low of $1.22.
    • Powerbridge Technologies (NASDAQ:PBTS) shares hit a yearly low of $0.29. The stock was down 4.59% on the session.
    • Freight Technologies (NASDAQ:FRGT) stock hit a new 52-week low of $0.63. The stock was down 1.68% on the session.
    • Takung Art (AMEX:TKAT) stock set a new 52-week low of $0.18 on Thursday, moving down 15.97%.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares set a new 52-week low of $2.88. The stock traded down 2.68%.
    • Ault Alliance (AMEX:AULT) shares set a new 52-week low of $2.95. The stock traded down 10.86%.
    • C3is (NASDAQ:CISS) stock broke to a new 52-week low of $0.62 on Thursday. Shares of the company traded down 3.64%.
    • Avalo Therapeutics (NASDAQ:AVTX) shares set a new 52-week low of $0.21. The stock traded down 7.75%.
    • Aditxt (NASDAQ:ADTX) shares moved up 0.1% on Thursday to hit a new 52-week low of $0.39, drifting up 0.1%.
    • BitNile Metaverse (NASDAQ:BNMV) shares fell to $0.74 on Thursday, setting a new 52-week low with a shift of down 7.99%.
    • Esports Entertainment (NASDAQ:GMBL) stock achieved a new 52-week low on Thursday morning, hitting $0.42 and moving down 7.98%.
    • American Rebel Holdings (NASDAQ:AREB) shares were down 4.93% for the day, having made a 52-week low of $1.56.

    Be sure to stay with Benzinga for further updates and market-moving news. And if you want to be among the first to know about the 52-week highs and lows for the day, check out Benzinga Pro. Users receive a daily alert listing stocks trading near 52-week highs and lows each morning. Click here to learn more.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $ACXP
    $ADTX
    $AREB

    CompanyDatePrice TargetRatingAnalyst
    MaxLinear Inc.
    $MXL
    4/24/2026$60.00Neutral → Buy
    Roth Capital
    MaxLinear Inc.
    $MXL
    4/24/2026$60.00Hold → Buy
    Needham
    TC Energy Corporation
    $TRP
    4/23/2026Neutral → Sector Outperform
    CIBC
    TC Energy Corporation
    $TRP
    4/20/2026$62.00Sell → Neutral
    Goldman
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Nexa Resources S.A.
    $NEXA
    4/9/2026Underweight → Equal-Weight
    Morgan Stanley
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    uniQure N.V.
    $QURE
    3/11/2026$35.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:50:38 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:48:25 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:43:04 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    SEC Filings

    View All

    SEC Form 6-K filed by Nexa Resources S.A.

    6-K - Nexa Resources S.A. (0001713930) (Filer)

    4/24/26 7:43:07 AM ET
    $NEXA
    Metal Mining
    Basic Materials

    SEC Form 20-F filed by Yunji Inc.

    20-F - Yunji Inc. (0001759614) (Filer)

    4/24/26 6:32:51 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Prelude Therapeutics Incorporated

    SCHEDULE 13D/A - Prelude Therapeutics Inc (0001678660) (Subject)

    4/23/26 8:42:51 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:50:38 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Orbimed Advisors Llc bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

    4 - Prelude Therapeutics Inc (0001678660) (Issuer)

    4/23/26 6:48:25 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Hrt Financial Lp bought $24,061 worth of Class A Shares (72,912 units at $0.33) and sold $3,595 worth of Class A Shares (11,982 units at $0.30), increasing direct ownership by 100% to 121,592 units (SEC Form 4)

    4 - Aditxt, Inc. (0001726711) (Issuer)

    4/23/26 3:43:04 PM ET
    $ADTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MaxLinear upgraded by Roth Capital with a new price target

    Roth Capital upgraded MaxLinear from Neutral to Buy and set a new price target of $60.00

    4/24/26 8:33:10 AM ET
    $MXL
    Semiconductors
    Technology

    MaxLinear upgraded by Needham with a new price target

    Needham upgraded MaxLinear from Hold to Buy and set a new price target of $60.00

    4/24/26 8:00:47 AM ET
    $MXL
    Semiconductors
    Technology

    TC Energy upgraded by CIBC

    CIBC upgraded TC Energy from Neutral to Sector Outperform

    4/23/26 11:56:01 AM ET
    $TRP
    Natural Gas Distribution
    Utilities

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nexa Resources Publishes 2025 Sustainability Report

    Luxembourg, Luxembourg--(Newsfile Corp. - April 24, 2026) - Nexa Resources S.A. (NYSE:NEXA) ("Nexa Resources", "Nexa" or the "Company") today published its 2025 Sustainability Report, covering the period from January 1 to December 31, 2025. The report underscores the Company's ongoing commitment to corporate sustainability and socially responsible practices, while detailing initiatives and achievements across its operations environment, workforce, and communities.It has been prepared in accordance with the frameworks of the International Integrated Reporting Council ("IIRC") and to the Global Reporting Initiative ("GRI") and also aligns with the Sustainability Accounting Standards Board ("SA

    4/24/26 7:50:00 AM ET
    $NEXA
    Metal Mining
    Basic Materials

    Yunji Files 2025 Annual Report on Form 20-F

    HANGZHOU, China, April 24, 2026 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ:YJ), a leading membership-based social e-commerce platform, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 24, 2026 Eastern Time. The annual report can be accessed on the Company's investor relations website at https://investor.yunjiglobal.com. The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be submitted to [email protected] Yunji

    4/24/26 7:30:00 AM ET
    $YJ
    Other Specialty Stores
    Consumer Discretionary

    Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company

    Expands Options for Cash-Paying Patients to Access the Nation's #1 Prescribed Oral Blood Thinner The Bristol Myers Squibb-Pfizer (NYSE:BMY) — (NYSE:PFE) Alliance today announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis® (apixaban) on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral anticoagulants in the United States and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication. "The BMS-Pfizer Alliance is pleased to expand our direct-to-patient options

    4/24/26 6:59:00 AM ET
    $BMY
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Leadership Updates

    Live Leadership Updates

    View All

    Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

    WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company. "I am thrilled to welcome Felecia as our new Chief Legal Officer," said Mik

    4/20/26 8:00:00 AM ET
    $ARDX
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

    WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude Therapeutics" or the "Company"), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026. "We are thrilled to welcome Dr. Charles Morris to Prelude Therapeutics as Executive Vice President and Chief Medical Officer," stated Kris Vaddi, Chief Executive Officer of Prelude Therapeutics. "With our two lead programs targeting myeloproliferative neoplasms and ER+ breast cancer advancing expected to enter into clinical development in 2026, Dr. Morris's deep clinical experience, track re

    4/15/26 7:30:00 AM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Financials

    Live finance-specific insights

    View All

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update

    STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:Date:                       Tuesday, May 12, 2026Time:                       8:00 a.m. ET Toll fr

    4/20/26 8:00:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Luxfer Announces Date of First Quarter 2026 Earnings Conference Call

    Luxfer Holdings PLC (NYSE:LXFR) ("Luxfer" or the "Company"), a global industrial company innovating niche applications in materials engineering, today announced the following details for its first quarter 2026 conference call. Date and time: Wednesday April 29, 2026, at 8:30 a.m. Eastern Time     Luxfer participants: Andy Butcher Chief Executive Officer Steve Webster Chief Financial Officer Kevin Grant Vice President of Investor Relations and Business Development     Dial-in registration: United States or Canada: 800-343-4136 International: (+1) 203-518-9843 Conference ID: LXFRQ

    4/15/26 4:45:00 PM ET
    $LXFR
    Major Chemicals
    Basic Materials

    $ABVC
    $ACXP
    $ADTX
    $AREB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by MSP Recovery Inc.

    SC 13D/A - MSP Recovery, Inc. (0001802450) (Subject)

    12/17/24 4:05:04 PM ET
    $LIFW
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care